NFATc4 has been described as a new mechanism that contributes to the induction of pathological cardiac hypertrophy [22] Interestingly, short-term treatment of SHR with esmolol significantly reduced p-NFATc4 levels. The gene discussed is NFATC4; the disease is cardiac hypertrophy.